An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
Latest Information Update: 04 Oct 2024
At a glance
- Drugs KN 5501 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Antisynthetase syndrome; Rheumatoid arthritis
- Focus Adverse reactions
- 04 Oct 2024 New trial record